SMT C1100 - A Phase 1, Open-label, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Paediatric Patients with Duchenne Muscular Dystrophy

Trial Profile

SMT C1100 - A Phase 1, Open-label, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Paediatric Patients with Duchenne Muscular Dystrophy

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Ezutromid (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Sponsors Summit plc
  • Most Recent Events

    • 30 Sep 2015 Results published in Summit Therapeutics media release.
    • 03 Jul 2014 Results published in the Media Release.
    • 03 Jul 2014 According to a Summit plc media release, top-line results were reported in May 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top